7 HLTH Announcements You Don’t Want to Miss

As always, this year’s HLTH conference brought a slew of announcements — from product launches to funding rounds to new partnerships. This list features short summaries for seven of the conference’s most notable announcements. The post 7 HLTH Announcements You Don’t Want to Miss appeared first on MedCity News.

Read More

Is Optum Real For Real?

Providers increasingly accuse payers of delaying and denying reimbursement for claims. Now, UnitedHealth Group’s Optum subsidiary is hoping to change the dynamic through what they claim is a real-time claims management program leveraging tech. The post Is Optum Real For Real? appeared first on MedCity News.

Read More

Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm

In a placebo-controlled mid-stage study, Ventyx Biosciences’ oral NLRP3 inhibitor led to rapid and sustained reductions in levels of a protein that’s an indicator of cardiovascular disease risk. The brain-penetrating properties of this once-daily pill also have potential applications addressing inflammation that drives neurodegenerative disorders. The post Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set…

Read More

Takeda Boosts Pipeline and Revenue Growth Prospects With $1.2B Deal for Innovent Cancer Drugs

Takeda’s agreement with Innovent Biologics brings cancer drugs that could become contributors to a portfolio that’s facing the patent cliff. The pharmaceutical giant’s strategy for finding new blockbuster prospects spans internally discovered drugs and in-licensed assets. The post Takeda Boosts Pipeline and Revenue Growth Prospects With $1.2B Deal for Innovent Cancer Drugs appeared first on…

Read More